Journal
CLINICA CHIMICA ACTA
Volume 412, Issue 23-24, Pages 2211-2215Publisher
ELSEVIER
DOI: 10.1016/j.cca.2011.08.008
Keywords
CCN2; Connective tissue growth factor (CTGF); Biomarker; Idiopathic pulmonary fibrosis (IPF); Idiopathic interstitial pneumonias (IIPs); Enzyme-linked immunosorbent assay (ELISA)
Categories
Funding
- Grants-in-Aid for Scientific Research [23659295, 22590855, 21390180] Funding Source: KAKEN
Ask authors/readers for more resources
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and fatal pulmonary fibrotic disease and useful biomarkers are required to diagnose and predict disease activity. CCN2 (connective tissue growth factor; CTGF) has been reported as one of the key profibrotic factors associated with transforming growth factor-beta (TGF-beta), and its assay has potential as a non-invasive measure in various fibrotic diseases. Recently, we developed a new subtraction method for determination of plasma CCN2 levels. We examined the utility of plasma CCN2 levels as a surrogate marker in IPF. Methods: Plasma CCN2 levels were calculated in 33 patients with IPF, 14 patients with non-IPF idiopathic interstitial pneumonias (IIPs) and 101 healthy volunteers by sandwich enzyme-linked immunosorbent assay (ELISA) using specific monoclonal antibodies for two distinct epitopes of human CCN2. We evaluated the utility of plasma CCN2 levels by comparison with clinical parameters. Results: Plasma CCN2 levels were significantly higher in patients with IPF than in those with non-IPF IIPs and healthy volunteers. Importantly, plasma CCN2 levels showed significantly negative correlation with 6-month change of forced vital capacity (FVC) in patients with IPF. Conclusions: Plasma CCN2 is a potential biomarker for IPF. (C) 2011 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available